A systematic review on UROMUNE™ (MV140) has been published. All relevant clinical studies published have been considered to globally assess the impact of this vaccine in the treatment of recurrent urinary tract infections.
UROMUNE™ (MV140) is a sublingual bacterial vaccine developed by INMUNOTEK designed to prevent recurrent urinary tract infections (rUTI). In the vast majority of cases, rUTI affect women in form of recurrent cystitis. As UTIs are caused by bacteria, the conventional treatment is based on antibiotics.
The review, published in Can Urol Assoc J, has assessed the clinical benefit provided by UROMUNE™ (MV140) in the prevention of this type of pathology from published clinical data. Authors concluded that this vaccine can be an alternative to prophylactic antibiotics to avoid the infection recurrence.
Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada?
A systematic review of the current literature and plans for the future.
J. Curtis Nickel, MD, FRCSC, corresponding author(1), Paula Saz-Leal, PhD,(2) and R. Christopher Doiron, MD(1)
UROMUNE™ was developed by Inmunotek, an innovative pharmaceutical company based in Spain. The product is exclusively licensed in Canada to Red Leaf Medical. The company intends to file a new drug submission for UROMUNE™ with Health Canada in Q4 2021.
CUAJ Published study – click here.